Chemistry:Vofopitant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | GR205171; GR-205171 |
| Routes of administration | Oral |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H23F3N6O |
| Molar mass | 432.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vofopitant (GR205171) is a drug which acts as an NK1 receptor antagonist. It has antiemetic effects as with other NK1 antagonists,[1] and also shows anxiolytic actions in animals.[2] It was studied for applications such as the treatment of social phobia and post-traumatic stress disorder, but did not prove sufficiently effective to be marketed.[3][4]
See also
- NK1 receptor antagonist
References
- ↑ "GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity". Regulatory Peptides 65 (1): 45–53. August 1996. doi:10.1016/0167-0115(96)00071-7. PMID 8876035.
- ↑ "Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils". Behavioural Pharmacology 20 (7): 584–95. October 2009. doi:10.1097/FBP.0b013e32832ec594. PMID 19675456.
- ↑ "Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo". Biological Psychiatry 58 (2): 132–42. July 2005. doi:10.1016/j.biopsych.2005.03.029. PMID 16038684.
- ↑ "A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial". European Neuropsychopharmacology 21 (3): 221–9. March 2011. doi:10.1016/j.euroneuro.2010.11.012. PMID 21194898.
 |  |
